
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics Inc's stock outlook is bolstered by an increased EV/Sales multiple to 9.5x, reflecting the company's significant growth potential driven by upcoming milestone payments and royalties, which are expected to yield high margins. The company's pipeline products, particularly icotrokinra, demonstrate promising efficacy enhancements projected to capture substantial market share in conditions like ulcerative colitis (UC) and psoriasis (PsO), with peak unadjusted revenues estimated to reach $3.2 billion and $3 billion, respectively. Additionally, the potential success of preclinical programs in obesity and hepcidin-related treatments could further enhance investor sentiment and contribute to share price appreciation.
Bears say
Protagonist Therapeutics Inc. faces significant regulatory risks that could potentially delay or prevent the approval of its pipeline assets, adversely affecting future cash flows and share price. The company continues to incur net losses, suggesting a reliance on additional capital raises to complete drug development, which may dilute shareholder value. Furthermore, the company may encounter challenges in clinical trial recruitment and potential serious side effects of its product candidates, further complicating their market entry and acceptance.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares